Feline dysautonomia, also known as Key-Gaskell syndrome, is a rare but devastating neurodegenerative disorder characterized by widespread degeneration of the autonomic nervous system (ANS).
Overview and Clinical Importance
Feline dysautonomia, also known as Key-Gaskell syndrome, is a rare but devastating neurodegenerative disorder characterized by widespread degeneration of the autonomic nervous system (ANS). First described in 1982 in the United Kingdom, this condition affects both sympathetic and parasympathetic divisions, resulting in multisystemic dysfunction affecting the gastrointestinal tract, urinary system, cardiovascular system, and ocular structures.
The disease carries a poor prognosis with mortality rates of 70-80% reported in most studies. Understanding the clinical presentation, diagnostic approach, and supportive care options is essential for the NAVLE, as this condition exemplifies autonomic nervous system pathophysiology and its multisystemic consequences.
High-YieldFeline dysautonomia is characterized by the classic triad of mydriasis (dilated pupils), megaesophagus, and constipation. When you see a young cat with these three findings plus dry mucous membranes and prolapsed third eyelids, dysautonomia should be at the top of your differential list.
| Proposed Etiology |
Supporting Evidence |
| Clostridium botulinum toxin (Type C/D) |
Association found in some outbreak studies; similar to equine grass sickness mechanism |
| Environmental toxin |
Regional clustering of cases suggests environmental exposure; possibly contaminated food or water |
| Infectious agent |
Outbreaks in closed colonies suggest possible transmissible agent; not definitively identified |
Etiology and Epidemiology
Proposed Etiologies
The exact cause of feline dysautonomia remains unknown. However, several theories have been proposed based on epidemiological patterns and pathological findings.
Epidemiological Features
- Age: Any age affected; median age 3.9 years; more common in younger cats (less than 3 years)
- Sex: No sex predisposition documented
- Breed: No breed predisposition; all breeds affected
- Geographic distribution: Originally widespread in UK (1982-1986); now reported in Europe, US (especially Midwest - Kansas, Missouri, Oklahoma, California), New Zealand, UAE
- Environment: Rural environments may be at higher risk; outdoor access cats more commonly affected
| Organ System |
Sympathetic Function Lost |
Parasympathetic Function Lost |
| Eye |
Third eyelid retraction (causes prolapse) |
Pupil constriction (causes mydriasis), lacrimation (causes dry eye) |
| Heart |
Increased heart rate |
Heart rate regulation (may cause bradycardia) |
| GI Tract |
GI motility inhibition |
GI motility stimulation (causes ileus, megaesophagus, constipation) |
| Urinary Bladder |
Internal sphincter relaxation |
Detrusor contraction (causes urinary retention) |
| Secretory Glands |
Vasoconstriction |
Salivation, nasal secretions (causes dry nose/mouth) |
Pathophysiology
Feline dysautonomia results from chromatolytic degeneration of neurons within autonomic ganglia. The degenerative process affects both sympathetic and parasympathetic divisions, leading to widespread autonomic failure.
Histopathological Findings
- Chromatolysis: Dissolution of Nissl bodies (rough endoplasmic reticulum) in neuronal cell bodies
- Neuronal degeneration: Affects pre- and postganglionic sympathetic and parasympathetic neurons
- Ganglia affected: Sympathetic chain ganglia, parasympathetic ganglia, dorsal root ganglia, cranial nerve ganglia
- CNS involvement: Chromatolytic changes in ventral horn neurons of spinal cord and brainstem cranial nerve nuclei
Autonomic Nervous System Functions Affected
| Clinical Sign |
Frequency |
ANS Division |
| Anorexia/Hyporexia |
92% |
Both |
| Reduced lacrimation (Schirmer less than 5 mm/min) |
90% |
Parasympathetic |
| Absent/delayed pupillary light reflex |
88% |
Parasympathetic |
| Regurgitation/Vomiting |
85% |
Parasympathetic |
| Mydriasis (dilated pupils) |
81% |
Parasympathetic |
| Third eyelid protrusion |
77% |
Sympathetic |
| Megaesophagus |
65-89% |
Parasympathetic |
| Constipation |
55% |
Parasympathetic |
| Dry nose/nasal crusting |
46% |
Parasympathetic |
| Lower urinary tract signs |
43% |
Parasympathetic |
| Bradycardia |
30% |
Sympathetic |
| Altered anal tone |
20% |
Both |
| Aspiration pneumonia |
13% |
Secondary |
Clinical Signs and Presentation
Clinical signs typically develop acutely (within 48 hours in most cases) and reflect dysfunction of both sympathetic and parasympathetic divisions. The onset can range from a few hours to several weeks.
Clinical Signs by Frequency
NAVLE TipThe NAVLE classic presentation is a young cat with the triad of dilated unresponsive pupils (mydriasis), megaesophagus causing regurgitation, and constipation, along with dry mucous membranes and prolapsed third eyelids. Remember: "My cat can't See, can't Swallow, can't Stool" (3 S's of dysautonomia).
| Test |
Protocol |
Normal Response |
Dysautonomia Response |
| Dilute Pilocarpine Test |
0.05-0.1% pilocarpine, 1 drop in one eye, observe 30-60 min |
No effect (normal innervation prevents hypersensitivity) |
Miosis within 30-45 minutes (positive in approximately 80% of cases) |
| Atropine Challenge Test |
Atropine 0.04-0.06 mg/kg SC, monitor HR 5-20 min |
Tachycardia (HR greater than 140 bpm) |
No increase in heart rate (loss of vagal tone) |
| Intradermal Histamine Test |
0.05 mL of 1:10,000 histamine intradermally |
Wheal AND flare response |
Wheal only, no flare (loss of sympathetic vasodilation) |
| Schirmer Tear Test |
Standard tear test strip, 1 minute |
Greater than 15 mm/min |
Less than 5 mm/min (reduced lacrimation) |
Diagnosis
Diagnosis of feline dysautonomia is based on clinical signs, physical examination findings, pharmacologic testing, and radiographic abnormalities. Definitive diagnosis requires histopathological examination of autonomic ganglia.
Pharmacologic Testing
Pharmacologic tests exploit denervation hypersensitivity, where postganglionic targets become hyperresponsive to neurotransmitters following loss of innervation.
High-YieldThe dilute pilocarpine test works because of DENERVATION HYPERSENSITIVITY. When parasympathetic postganglionic neurons degenerate, the iris sphincter muscle becomes hypersensitive to direct-acting cholinergic agonists like pilocarpine. A 0.05% solution that would have no effect on a normal cat causes rapid miosis in dysautonomia. A negative test does NOT rule out dysautonomia (10-15% false negatives).
Radiographic Findings
Thoracic and abdominal radiographs provide supportive evidence for dysautonomia and help assess complications.
- Megaesophagus: Gas or fluid-filled dilated esophagus; "tracheal stripe sign" (soft tissue line between trachea and esophagus outlined by gas)
- Aspiration pneumonia: Alveolar pattern, especially in right middle lung lobe and cranioventral lung fields
- Gastric distension: Dilated stomach with gas/fluid accumulation
- Intestinal ileus: Generalized intestinal distension with gas
- Urinary bladder distension: Large, distended bladder on abdominal radiographs
- Megacolon: Fecal retention with colonic distension
Differential Diagnosis
| Condition |
Distinguishing Features |
| Feline Leukemia Virus (FeLV) |
Can cause anisocoria and urinary incontinence; test FeLV antigen (dysautonomia cats typically negative) |
| Myasthenia Gravis |
Megaesophagus present but no ocular signs; positive acetylcholine receptor antibody test |
| Idiopathic Megaesophagus |
Isolated esophageal dysfunction; no other autonomic signs |
| Lead Toxicity |
Megaesophagus with neurologic signs; blood lead levels elevated |
| Glaucoma |
Causes mydriasis; elevated intraocular pressure (IOP); no systemic signs |
| Botulism |
Acute flaccid paralysis; may have similar GI signs; exposure history |
Treatment and Management
There is no definitive treatment for feline dysautonomia. Management is entirely supportive and symptomatic. The goal is to maintain hydration, nutrition, and organ function while allowing potential neuronal recovery (which may take up to 1 year).
Supportive Care by System
Exam Focus: When treating dysautonomia, the MOST IMPORTANT supportive care measures are: (1) Fluid therapy to correct dehydration, (2) Nutritional support via feeding tube, (3) Bladder expression to prevent urinary retention and secondary UTI. Aspiration pneumonia secondary to megaesophagus is the leading cause of death.
| System |
Management |
Medications/Notes |
| Fluid/Electrolytes |
IV fluid therapy initially; maintain hydration |
Lactated Ringer's or 0.9% NaCl; correct dehydration |
| Nutrition |
Feeding tube placement; elevated feeding position if possible |
Nasogastric, esophagostomy, or gastrostomy tube; maintain upright 10-15 min post-feeding |
| GI Motility |
Prokinetic agents; laxatives for constipation |
Metoclopramide 0.1-0.3 mg/kg SC/IV q8h; Cisapride 1 mg/kg PO q8-12h; Lactulose for constipation |
| Urinary |
Manual bladder expression TID; parasympathomimetic if needed |
Bethanechol 1-2.5 mg/cat PO q8-12h (use with caution; atropine is antidote for overdose) |
| Ocular |
Artificial tears; protect cornea |
Artificial tears q2-4h; ophthalmic lubricant at night |
| Respiratory |
Humidification; treat aspiration pneumonia if present |
Steam inhalation; broad-spectrum antibiotics for pneumonia |
| General |
Keep warm; assist with grooming |
Provide warmth; nursing care for grooming/hygiene |
Prognosis
The prognosis for feline dysautonomia is poor to guarded. Understanding prognostic factors helps guide client communication and treatment decisions.
Negative Prognostic Indicators
- Prolonged anorexia
- Frequent regurgitation or vomiting
- Severe megaesophagus
- Non-responsive fecal or urinary retention
- Aspiration pneumonia
- Bradycardia (worse prognosis than normal heart rate)
- Multiple organ system involvement
Positive Prognostic Indicators
- Milder clinical signs
- Clinical signs limited to single body system
- Ability to maintain body weight with oral consumption
- Normal heart rate
- Absence of urinary and fecal incontinence
| Outcome Measure |
Statistics |
| Overall mortality rate |
70-80% (2020 study: 80% mortality) |
| Survival to discharge |
29% of cats |
| Long-term survival (greater than 2 years) |
21% overall survival |
| Death within 2 months of onset |
Nearly 50% |
| Complete resolution (if survived) |
Approximately 25%; may take up to 1 year |